Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: Hans U. Tschanz who wrote (42)	2/20/2000 2:49:00 PM
From: swisstrader	Respond to of 598

News (see below...brief but still news)...Hans: my (latest) purchase was at 89 5/8 about 10 mins before closing bell...we keep banging out new 52 week highs here...think the only reason for some slowing was the mkts in general and still gained on the day! Friday February 18, 2:38 pm Eastern Time Licensing, biotech frenzy fuels Techniclone rally LOS ANGELES, Feb 18 (Reuters) - Shares of cancer treatment developer Techniclone Inc. (NasdaqSC:TCLN - news) soared more than 30 percent on Friday amid renewed investor interest after recent patents and licensing fueled overall enthusiasm for biotechnology stocks. Shares of the Tustin, Calif.-based company were up 2-9/16 at 8-9/16 on Nasdaq after hitting a new 52-week high of 9-1/4 earlier in the day. ``We have had numerous calls from investors who were very interested to see whether Techniclone would be able to come through on licensing agreements,' said Marjorie Hays, a spokeswoman for the company. On Tuesday Techniclone announced the completion of an exclusive worldwide licensing deal with the University of Southern California for a permeability-enhancing protein used to increase the uptake of chemotherapeutic drugs into tumors. The company also said it was issued a U.S. patent for the protein, but further terms of the licensing agreement were not disclosed. Techniclone said the protein covered by the licensing deal gives the company complete access to a technology that fits very well into the drug development efforts of many pharmaceutical companies. ``The whole biotech sector is really coming into the fore, creating enormous attention for the company,' Hays said. As recently as last December, Techniclone's shares were trading at less than 50 cents a share after the company acknowledged defaulting on a $3.3 million loan, its interim chairman resigned and clinical trials of its direct tumor targeting agent, Oncolym, were halted. At the time, the company warned that it was in danger of being delisted from the Nasdaq exchange unless the price of its shares reached $1.00 for a sustained period. Meanwhile, several other biotechnology stocks continued on Friday to extend their recent run-ups with the Nasdaq biotech index up 2.38 percent in morning trading. Shares of early-stage drug development companies Hyseq Inc. (NasdaqNM:HYSQ - news) and Tularik Inc. (NasdaqNM:TLRK - news) were up 4-13/16 at 125-1/16 and 5-5/8 at 92-3/4, respectively. Shares of Millennium Pharmaceuticals Inc. (NasdaqNM:MLNM - news) were up 45-1/16 at 269-1/2, while Gene Logic Inc.'s (NasdaqNM:GLGC - news) stock was up 7-23/32 at 109-1/2.

To: Hans U. Tschanz who wrote (42)	2/26/2000 2:30:00 AM
From: swisstrader	Read Replies (1) \| Respond to of 598

Hans: I guess the reason for the recent downdraft: Wednesday February 23, 6:39 pm Eastern Time Company Press Release SOURCE: Tularik Inc. Tularik Inc. Files Registration Statement for Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., Feb. 23 /PRNewswire/ -- Tularik Inc. (Nasdaq: TLRK - news) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed public offering of 5,000,000 shares of common stock, including 3,750,000 shares expected to be offered by Tularik and 1,250,000 shares expected to be offered by selling stockholders. The offering is being made through an underwriter group managed by Lehman Brothers Inc., J.P. Morgan & Co., Chase H & Q, Thomas Weisel Partners LLC and Warburg Dillon Read LLC. Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs based on gene regulation. Tularik programs address cancer, CMV, diabetes, obesity, inflammation, allergy/asthma, hypercholesterolemia, bacterial diseases and a class of drug targets known as orphan nuclear receptors. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.